FDA
-
-
-
-
-
-
-
GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)
-
-
-
-
-
-
-
GENFIT (GNFT) to Acquire Versantis
-
-
-
-
-
-
-
New Clinical Data on GENFIT’s Investigational Compound Elafibranor to be Presented at AASLD The Liver Meeting®
-
-
-
-
-
-
-
GENFIT Announces First Patient First Visit for ELATIVE Phase 3 Study Evaluating Elafibranor in PBC
-
-
-
-
-
-
-
Correction - GENFIT: Unblinding of Phase 3 RESOLVE-IT Data Deferred
-
-
-
-
-
-
-
GENFIT Announces New Data to be Presented at AASLD Liver Meeting 2019
-
-
-
-
-
-
-
GENFIT: GENFIT and Terns Pharmaceuticals Announce $228MM Strategic Partnership to Develop and Commercialize Elafibranor in Greater China
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

